Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B

Journal of Clinical Oncology

Volumn 31, Issue 22, 2013, Pages 2765-2772

  Huang, Yi Hsiang ^a,b   Hsiao, Liang Tsai ^a,b   Hong, Ying Chung ^a   Chiou, Tzeon Jye ^a,b   Yu, Yuan Bin ^a,b   Gau, Jyh Pyng ^a,b   Liu, Chun Yu ^a,b   Yang, Muh Hwa ^a,b   Tzeng, Cheng Hwai ^a,b   Lee, Pui Ching ^a   Lin, Han Chieh ^a,b   Lee, Shou Dong ^c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; PREDNISOLONE; RITUXIMAB; VINCRISTINE; VIRUS DNA; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VIRUS LOAD; VIRUS REACTIVATION; BLOOD; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; MIDDLE AGED; PHYSIOLOGY; VERY ELDERLY; VIROLOGY; VIRUS ACTIVATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; VIRUS ACTIVATION;

EID: 84884755581     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.5938     Document Type: Article

References (30)

1. Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11:97-107, 2004
2. Ganem D, Prince AM: Hepatitis B virus infection: Natural history and clinical consequences. N Engl J Med 350:1118-1129, 2004
3. Lok AS, McMahon BJ: Chronic hepatitis B: Update 2009. Hepatology 50:661-662, 2009
4. Hoofnagle JH: Reactivation of hepatitis B. Hepatology 49:S156-S165, 2009
5. Huang YH, Lin HC, Lee SD: Management of chemotherapy-induced hepatitis B virus reactivation. J Chin Med Assoc 75:359-362, 2012
6. Yeo W, Zee B, Zhong S, et al: Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90:1306-1311, 2004
7. Lau GK, Yiu HH, Fong DY, et al: Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125:1742-1749, 2003
8. Hsu C, Hsiung CA, Su IJ, et al: A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. Hepatology 47:844-853, 2008
9. Czuczman MS, Grillo-López AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999
10. Evens AM, Jovanovic BD, Su YC, et al: Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Meta-analysis and examination of FDA safety reports. Ann Oncol 22:1170-1180, 2011
11. Wu JM, Huang YH, Lee PC, et al: Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma. J Clin Gastroenterol 43:496-498, 2009
12. Lee IC, Huang YH, Chu CJ, et al: Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma. J Chin Med Assoc 73:156-160, 2010
13. Koo YX, Tan DS, Tan IB, et al: Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 116:115-121, 2010
14. Pei SN, Chen CH, Lee CM, et al: Reactivation of hepatitis B virus following rituximab-based regimens: A serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 89:255-262, 2010
15. Matsue K, Kimura S, Takanashi Y, et al: Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 116:4769-4776, 2010
16. Yeo W, Chan TC, Leung NW, et al: Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27:605-611, 2009
17. Sarrecchia C, Cappelli A, Aiello P: HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 11:189-191, 2005
18. Law JK, Ho JK, Hoskins PJ, et al: Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: Potential implications for future prophylaxis recommendations. Leuk Lymphoma 46:1085-1089, 2005
19. Hui CK, Cheung WW, Zhang HY, et al: Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131:59-68, 2006
20. Yeo W, Chan PK, Ho WM, et al: Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22:927-934, 2004
21. Yeo W, Johnson PJ: Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43:209-220, 2006
22. Liaw YF, Leung N, Kao JH, et al: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 2:263-283, 2008
23. European Association for the Study of the Liver: EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 50:227-242, 2009
24. Hui CK, Cheung WW, Au WY, et al: Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 54:1597-1603, 2005
25. Dai MS, Chao TY, Kao WY, et al: Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 83:769-774, 2004
26. Fukushima N, Mizuta T, Tanaka M, et al: Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 20:2013-2017, 2009
27. Raimondo G, Pollicino T, Cacciola I, et al: Occult hepatitis B virus infection. J Hepatol 46:160-170, 2007
28. European Association for the Study of the Liver: EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57:167-185, 2012
29. Liaw YF, Kao JH, Piratvisuth T, et al: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatol Int doi:10.1007/s12072-012-9365-4
30. Zurawska U, Hicks LK, Woo G, et al: Hepatitis B virus screening before chemotherapy for lymphoma: A cost-effectiveness analysis. J Clin Oncol 30:3167-3173, 2012